[go: up one dir, main page]

SG11201501923WA - 2-oxo-2,3-dihydro-indoles for the treatment of cns disorders - Google Patents

2-oxo-2,3-dihydro-indoles for the treatment of cns disorders

Info

Publication number
SG11201501923WA
SG11201501923WA SG11201501923WA SG11201501923WA SG11201501923WA SG 11201501923W A SG11201501923W A SG 11201501923WA SG 11201501923W A SG11201501923W A SG 11201501923WA SG 11201501923W A SG11201501923W A SG 11201501923WA SG 11201501923W A SG11201501923W A SG 11201501923WA
Authority
SG
Singapore
Prior art keywords
indoles
dihydro
oxo
treatment
cns disorders
Prior art date
Application number
SG11201501923WA
Inventor
Daniela Brunner
Jessica Malberg
Bavani G Shankar
Sabine Kolczewski
Anja Limberg
Eric Prinssen
Claus Riemer
Theodor Stoll
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47044777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201501923W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11201501923WA publication Critical patent/SG11201501923WA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201501923WA 2012-09-13 2013-09-10 2-oxo-2,3-dihydro-indoles for the treatment of cns disorders SG11201501923WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12184249 2012-09-13
PCT/EP2013/068668 WO2014040969A1 (en) 2012-09-13 2013-09-10 2-oxo-2,3-dihydro-indoles for the treatment of cns disorders

Publications (1)

Publication Number Publication Date
SG11201501923WA true SG11201501923WA (en) 2015-04-29

Family

ID=47044777

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201501923WA SG11201501923WA (en) 2012-09-13 2013-09-10 2-oxo-2,3-dihydro-indoles for the treatment of cns disorders

Country Status (22)

Country Link
US (1) US9221816B2 (en)
EP (1) EP2895476B1 (en)
JP (1) JP6116693B2 (en)
KR (1) KR101706877B1 (en)
CN (1) CN104619701B (en)
AR (1) AR092555A1 (en)
AU (1) AU2013314417B2 (en)
BR (1) BR112015005186A2 (en)
CA (1) CA2883817C (en)
CL (1) CL2015000559A1 (en)
CR (1) CR20150084A (en)
EA (1) EA027176B1 (en)
ES (1) ES2590531T3 (en)
IL (1) IL237266A0 (en)
MA (1) MA37943B1 (en)
MX (1) MX2015003330A (en)
PE (1) PE20150943A1 (en)
PH (1) PH12015500400A1 (en)
SG (1) SG11201501923WA (en)
TW (1) TWI490213B (en)
WO (1) WO2014040969A1 (en)
ZA (1) ZA201501262B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6130061B2 (en) * 2013-06-19 2017-05-17 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Indoline-2-one or pyrrolo-pyridine / pyrimidin-2-one derivatives
KR101898364B1 (en) * 2014-05-22 2018-09-12 에프. 호프만-라 로슈 아게 INDOLIN-2-ONE AND 1,3-DIHYDRO-PYRROLO[3,2-c]PYRIDIN-2-ONE DERIVATIVES
MY186124A (en) * 2014-06-26 2021-06-23 Hoffmann La Roche Indolin-2-one or pyrrolo-pyridin-2-one derivatives
CR20180255A (en) 2015-11-06 2018-06-22 Hoffmann La Roche DERIVATIVES OF INDOLIN-2-ONA
JP6857653B2 (en) 2015-11-06 2021-04-14 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Indoline-2-one derivatives for use in the treatment of CNS and related disorders
JP6857651B2 (en) 2015-11-06 2021-04-14 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Indoline-2-one derivatives useful in the treatment of CNS diseases
EP3371174B1 (en) 2015-11-06 2021-03-17 H. Hoffnabb-La Roche Ag Indolin-2-one derivatives
CN106065008B (en) * 2016-06-16 2018-06-05 黑龙江中医药大学 It is a kind of that there is the indoles -2- amides compounds for improving sleep effect and its application
GB201709456D0 (en) * 2017-06-14 2017-07-26 Ucb Biopharma Sprl Therapeutic agents
EP3870292A4 (en) 2018-10-26 2022-11-09 The Research Foundation for The State University of New York COMBINATION OF A SPECIFIC SEROTONIN REUPSORPTION INHIBITOR AND A SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA
CN119866338A (en) * 2022-06-23 2025-04-22 渤健马萨诸塞州股份有限公司 Tyrosine kinase 2 inhibitors and uses thereof
CN116640083A (en) * 2023-05-30 2023-08-25 江苏海洋大学 GPR52 modulator compound

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3417643A1 (en) 1984-05-12 1985-11-14 Boehringer Mannheim Gmbh, 6800 Mannheim Novel pyrrolobenzimidazoles, process for their preparation, medicaments containing these compounds and intermediates
PL147842B1 (en) 1984-05-12 1989-08-31 Method of obtaining novel pyroisobenzimidazoles
DE3445669A1 (en) 1984-12-14 1986-06-19 Boehringer Mannheim Gmbh, 6800 Mannheim NEW PYRROLO-BENZIMIDAZOLES, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
US4835280A (en) 1985-01-18 1989-05-30 Boehringer Mannheim Gmbh Indoline compounds for synthesis of pharmaceutically active pyrrolobenzimidazoles
DE3501497A1 (en) 1985-01-18 1986-07-24 Boehringer Mannheim Gmbh, 6800 Mannheim NEW PYRROLO-BENZIMIDAZOLES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND INTERMEDIATE PRODUCTS
DE3803775A1 (en) 1988-02-09 1989-08-17 Boehringer Mannheim Gmbh NEW SUBSTITUTED LACTAME, METHOD FOR THE PRODUCTION THEREOF, AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DE3818830A1 (en) 1988-06-03 1989-12-14 Boehringer Mannheim Gmbh BICYCLIC CARBOXAMIDS, METHOD FOR THE PRODUCTION THEREOF, AND THE MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DE3925584A1 (en) * 1989-08-02 1991-02-07 Boehringer Mannheim Gmbh NEW N- (DIMETHYLOXOPHOSPHINYLMETHYL -) LACTAME, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
JP2002522452A (en) 1998-08-04 2002-07-23 スージェン・インコーポレーテッド Regulator of protein kinase 3-methylidenyl-2-indolinone
JP2002540096A (en) 1999-03-24 2002-11-26 スージェン・インコーポレーテッド Indolinone compounds as kinase inhibitors
CN100562513C (en) * 2003-06-12 2009-11-25 安斯泰来制药有限公司 Benzamide derivatives or their salts
CA2526387A1 (en) * 2003-06-12 2004-12-23 Astellas Pharma Inc. Benzamide derivative or salt thereof
MX2007004781A (en) 2004-10-20 2007-05-11 Applied Research Systems 3-arylamino pyridine derivatives.
US20060142247A1 (en) 2004-12-17 2006-06-29 Guy Georges Tricyclic heterocycles
US8106190B2 (en) * 2005-11-30 2012-01-31 Astellas Pharma Inc. 2-aminobenzamide derivatives
KR20100039429A (en) * 2007-08-02 2010-04-15 에프. 호프만-라 로슈 아게 The use of benzamide derivatives for the treatment of cns disorders
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
WO2010123139A1 (en) * 2009-04-24 2010-10-28 持田製薬株式会社 Arylcarboxamide derivative having sulfamoyl group
AU2011326071A1 (en) * 2010-11-08 2013-05-23 Lycera Corporation N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of RORy activity and the treatment of diseases

Also Published As

Publication number Publication date
TWI490213B (en) 2015-07-01
AR092555A1 (en) 2015-04-22
PE20150943A1 (en) 2015-06-20
JP2015529673A (en) 2015-10-08
MA37943B1 (en) 2016-11-30
WO2014040969A1 (en) 2014-03-20
CA2883817A1 (en) 2014-03-20
KR20150054991A (en) 2015-05-20
PH12015500400A1 (en) 2015-04-27
MA37943A1 (en) 2016-04-29
EA027176B1 (en) 2017-06-30
HK1206721A1 (en) 2016-01-15
CR20150084A (en) 2015-04-06
ES2590531T3 (en) 2016-11-22
CN104619701A (en) 2015-05-13
US20150284386A1 (en) 2015-10-08
TW201416358A (en) 2014-05-01
AU2013314417B2 (en) 2016-01-21
US9221816B2 (en) 2015-12-29
BR112015005186A2 (en) 2017-07-04
JP6116693B2 (en) 2017-04-19
CL2015000559A1 (en) 2015-07-10
AU2013314417A1 (en) 2015-03-05
CA2883817C (en) 2017-09-05
IL237266A0 (en) 2015-04-30
EP2895476A1 (en) 2015-07-22
EA201590438A1 (en) 2015-06-30
EP2895476B1 (en) 2016-06-22
ZA201501262B (en) 2016-03-30
KR101706877B1 (en) 2017-02-15
CN104619701B (en) 2016-10-19
MX2015003330A (en) 2015-06-05

Similar Documents

Publication Publication Date Title
ZA201501262B (en) 2-oxo-2,3-dihydro-indoles for the treatment of cns disorders
IL237275A0 (en) Compounds for the treatment of paramoxyvirus viral infectiones
GB2503852B (en) Compounds for the treatment of neuropsychiatric disorders
LT2887944T (en) ALOPREGNANOLONE FOR THE TREATMENT OF RESISTANT EPILEPTIC CONDITION
EP2812298A4 (en) Improved process for the manufacture of 2,3,3,3-tetrafluoropropene
PT2875062T (en) Process for the synthesis of poly-aryl-ether-ketones
ZA201409194B (en) Biflourodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders
SI2906209T1 (en) D-methadone for the treatment of psychiatric symptoms
HRP20190038T1 (en) Pantothenate derivatives for the treatment of neurologic disorders
ZA201305970B (en) Arylosulfonami for the treatment of cns diseases
PT2861242T (en) Gluten-related disorders
ZA201504065B (en) Therapeutic agent for keratoconjunctive disorders
ZA201407506B (en) Sulphonamide derivatives of benzylamine for the treatment of cns diseases
IL237912B (en) Dihydro-6-azaphenalene derivatives for the treatment of cns, oncological diseases and related disorders
IL234796B (en) Compounds for the treatment of ischemia-reperfusion-related diseases
EP2970118A4 (en) Compounds for the treatment of neurological disorders
GB201207363D0 (en) Compounds for the treatment of metabolic disorders
GB201207359D0 (en) Compounds for the treatment of metabolic disorders
PL399603A1 (en) Process for the preparation of 3ß, 15α-dihydroxy-5α-androst-17-one
IL228973A (en) Oxymetazoline for the treatment of ano-rectal disorders